346 related articles for article (PubMed ID: 21255009)
1. Type I interferon supports primary CD8+ T-cell responses to peptide-pulsed dendritic cells in the absence of CD4+ T-cell help.
Ontiveros F; Wilson EB; Livingstone AM
Immunology; 2011 Apr; 132(4):549-58. PubMed ID: 21255009
[TBL] [Abstract][Full Text] [Related]
2. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo.
Stober D; Jomantaite I; Schirmbeck R; Reimann J
J Immunol; 2003 Mar; 170(5):2540-8. PubMed ID: 12594280
[TBL] [Abstract][Full Text] [Related]
3. Peptide-pulsed splenic dendritic cells prime long-lasting CD8(+) T cell memory in the absence of cross-priming by host APC.
Livingstone AM; Kuhn M
Eur J Immunol; 2002 Jan; 32(1):281-90. PubMed ID: 11782019
[TBL] [Abstract][Full Text] [Related]
4. Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells.
Bullock TN; Yagita H
J Immunol; 2005 Jan; 174(2):710-7. PubMed ID: 15634890
[TBL] [Abstract][Full Text] [Related]
5. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells.
Hermans IF; Silk JD; Gileadi U; Salio M; Mathew B; Ritter G; Schmidt R; Harris AL; Old L; Cerundolo V
J Immunol; 2003 Nov; 171(10):5140-7. PubMed ID: 14607913
[TBL] [Abstract][Full Text] [Related]
6. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells need T cell help to prime cytotoxic T cell responses to strong antigens.
Livingstone AM; Kuhn M
Eur J Immunol; 1999 Sep; 29(9):2826-34. PubMed ID: 10508257
[TBL] [Abstract][Full Text] [Related]
8. Active CD4+ helper T cells directly stimulate CD8+ cytotoxic T lymphocyte responses in wild-type and MHC II gene knockout C57BL/6 mice and transgenic RIP-mOVA mice expressing islet beta-cell ovalbumin antigen leading to diabetes.
Ye Z; Ahmed KA; Hao S; Zhang X; Xie Y; Munegowda MA; Meng Q; Chibbar R; Xiang J
Autoimmunity; 2008 Nov; 41(7):501-11. PubMed ID: 18855194
[TBL] [Abstract][Full Text] [Related]
9. H2-M3-restricted CD8+ T cells augment CD4+ T-cell responses by promoting DC maturation.
Chow MT; Teh HS
Eur J Immunol; 2010 May; 40(5):1408-17. PubMed ID: 20162552
[TBL] [Abstract][Full Text] [Related]
10. Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo.
Wang JC; Livingstone AM
J Immunol; 2003 Dec; 171(12):6339-43. PubMed ID: 14662830
[TBL] [Abstract][Full Text] [Related]
11. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
Machy P; Serre K; Baillet M; Leserman L
J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
[TBL] [Abstract][Full Text] [Related]
12. Whole protein and defined CD8(+) and CD4(+) peptides linked to penetratin targets both MHC class I and II antigen presentation pathways.
Pouniotis DS; Esparon S; Apostolopoulos V; Pietersz GA
Immunol Cell Biol; 2011 Nov; 89(8):904-13. PubMed ID: 21383765
[TBL] [Abstract][Full Text] [Related]
13. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
14. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
[TBL] [Abstract][Full Text] [Related]
15. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein.
Fujii S; Shimizu K; Smith C; Bonifaz L; Steinman RM
J Exp Med; 2003 Jul; 198(2):267-79. PubMed ID: 12874260
[TBL] [Abstract][Full Text] [Related]
16. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading.
Robson NC; Beacock-Sharp H; Donachie AM; Mowat AM
Immunology; 2003 Jul; 109(3):374-83. PubMed ID: 12807483
[TBL] [Abstract][Full Text] [Related]
18. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.
Pooley JL; Heath WR; Shortman K
J Immunol; 2001 May; 166(9):5327-30. PubMed ID: 11313367
[TBL] [Abstract][Full Text] [Related]
19. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
20. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
